Medical Devices

A CEO's personal battle with prostate cancer inspired a community golf tournament that is now on the verge of raising $1 million for critical research.

Backed by Bain Capital and a veteran team, the new biotech has a de-risked pipeline from Bristol Myers Squibb aimed at transforming care for lupus and more.

Investors eye BioCryst's May 6th report for insights into ORLADEYO's growth, a pivotal acquisition, and its strategy in the competitive rare disease market.

Promising early safety data for a novel drug, KM-023, brings a potential first-ever targeted treatment for the devastating Olmsted syndrome a step closer.

A first-in-class AI software, neuropacs™, gains FDA clearance, promising to help doctors differentiate complex Parkinsonian syndromes with high accuracy.

A new minimally invasive implant could revolutionize prosthetic control. Phantom Neuro's human trial in Australia marks a major step forward for amputees.

Philip Morris International's upcoming Q1 2026 earnings will be a crucial test of its pivot from cigarettes, with all eyes on ZYN's growth and regulatory hurdles.

A new strategic deal for the Lasix ONYU device aims to secure its key ingredient, transforming heart failure care from the hospital to the living room.

With $108M in new funding, Terremoto Biosciences advances a novel class of drugs designed to overcome the toxicities of past cancer treatments.

With a fresh $28M investment, Verismo Therapeutics is set to unveil groundbreaking KIR-CAR data, aiming to revolutionize CAR T therapy for solid tumors.

Atelerix's revolutionary hydrogel eliminates the need for cold chain logistics, partnering with JH Health to unlock the booming Saudi biotech market.

A quiet law change has unleashed affordable, over-the-counter hearing aids in the UK, but as millions stand to benefit, experts urge caution.

The new CE-Marked iREACH IRIS provides surgeons with real-time tissue data and unprecedented maneuverability, aiming to reduce surgical complications.

Shanghai's SinoUnited Health is attracting global patients with advanced care like CAR-T therapy at a fraction of US prices, challenging medical tourism hubs.

New NCCN guidelines include AI mammogram analysis, a major shift to identify hidden breast cancer risks for millions of women missed by traditional methods.

Phase 3 data shows GTx-104 reduces key risks and improves outcomes for aSAH patients, positioning it as a potential new standard of care ahead of an FDA decision.

A son's concern for his mother sparks an investment in a startup using AI to combat the hidden dangers of chronic dehydration affecting millions.

Oxford spinout Caristo Diagnostics appoints Stephen Deitsch, who led a $1.5B exit, as CEO to accelerate its mission of preventing heart attacks with AI.

Harrow partners with specialist LogiCare3PL for U.S. distribution, highlighting an industry shift towards agile, high-touch logistics for faster market access.

As Ontario hospitals face a financial crisis, a major innovation week aims to connect Canadian startups with global capital to solve healthcare's biggest challenges.